FOXO TECHNOLOGIES INC.

FOXO Technologies Inc. (NYSE American: FOXO) is a post-merger de-SPAC company operating in the insurtech and longevity science sector that went public in 2022 through a business combination with CF Acquisition Corp VIII, a blank-check vehicle sponsored by Cantor Fitzgerald. The company applies epigenetic biomarker technology to life insurance underwriting, aiming to modernize how insurers assess longevity risk. On July 6, 2026, FOXO filed an 8-K with the Securities and Exchange Commission under accession number 0001493152-26-032156, maintaining its status as an active SEC reporting company. For full filing timelines, sponsor profiles, and SPAC analytics on FOXO and hundreds of other de-SPAC issuers, sign up for complete data access at SpacDesk.